Drug Report History #179784
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-FR | Version v3-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated (Changed) | Updated to: 2023-03-06 | Was: 2023-01-04 |
| Drug Identification Number | 00897639 | 00897639 |
| Brand name | ISOPROTERENOL HYDROCHLORIDE INJECTION USP | ISOPROTERENOL HYDROCHLORIDE INJECTION USP |
| Common or Proper name | Isoproterenol | Isoproterenol |
| Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
| Ingredients | ISOPROTERENOL HYDROCHLORIDE | ISOPROTERENOL HYDROCHLORIDE |
| Strength(s) | 0.2MG | 0.2MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 10 x 1ML Ampoules | 10 x 1ML Ampoules |
| Additional packaging sizes | ||
| ATC code | C01CA | C01CA |
| ATC description | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
| Reason for shortage (Changed) | Updated to: Shortage of an active ingredient. | Was: Disruption of the manufacture of the drug. |
| Anticipated start date (Changed) | Updated to: | Was: 2023-01-01 |
| Actual start date (Changed) | Updated to: 2023-01-18 | Was: 2023-01-01 |
| Estimated end date (Changed) | Updated to: 2023-03-10 | Was: 2023-02-28 |
| Actual end date (Changed) | Updated to: 2023-03-06 | Was: |
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |